JNJ

190.39

-0.11%↓

ABT

127.23

+0.36%↑

MDT

93.84

+0.07%↑

VEEV

295.76

+0.87%↑

146.68

-1.03%↓

JNJ

190.39

-0.11%↓

ABT

127.23

+0.36%↑

MDT

93.84

+0.07%↑

VEEV

295.76

+0.87%↑

146.68

-1.03%↓

JNJ

190.39

-0.11%↓

ABT

127.23

+0.36%↑

MDT

93.84

+0.07%↑

VEEV

295.76

+0.87%↑

146.68

-1.03%↓

JNJ

190.39

-0.11%↓

ABT

127.23

+0.36%↑

MDT

93.84

+0.07%↑

VEEV

295.76

+0.87%↑

146.68

-1.03%↓

JNJ

190.39

-0.11%↓

ABT

127.23

+0.36%↑

MDT

93.84

+0.07%↑

VEEV

295.76

+0.87%↑

146.68

-1.03%↓

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Open

6.01 3.44

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.78

Max

6.77

Belangrijke statistieken
By Trading Economics
Inkomsten	453K -27M
Winstmarge	-2,027.003
Werknemers	81
EBITDA	408K -29M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+96.21% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	86M 280M
Vorige openingsprijs	2.57
Vorige sluitingsprijs	6.01

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 okt 2025, 23:52 UTC

Marktinformatie

Global Equities Roundup: Market Talk

26 okt 2025, 23:52 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

26 okt 2025, 23:46 UTC

Marktinformatie

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 okt 2025, 23:41 UTC

Marktinformatie

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 okt 2025, 23:34 UTC

Winsten

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 okt 2025, 23:32 UTC

Winsten

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 okt 2025, 23:30 UTC

Winsten

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 okt 2025, 22:29 UTC

Winsten

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 okt 2025, 22:29 UTC

Winsten

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 okt 2025, 22:29 UTC

Winsten

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 okt 2025, 22:29 UTC

Winsten

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 okt 2025, 22:16 UTC

Winsten

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 okt 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 okt 2025, 19:29 UTC

Acquisities, Fusies, Overnames

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 okt 2025, 06:39 UTC

Winsten

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 okt 2025, 06:39 UTC

Winsten

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 okt 2025, 06:39 UTC

Winsten

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 okt 2025, 21:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 okt 2025, 21:24 UTC

Marktinformatie

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 okt 2025, 21:07 UTC

Winsten

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 okt 2025, 20:58 UTC

Winsten

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 okt 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 20:40 UTC

Winsten

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 okt 2025, 20:24 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:23 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:13 UTC

Winsten

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 20:07 UTC

Marktinformatie

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 okt 2025, 19:40 UTC

Marktinformatie

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 okt 2025, 19:35 UTC

Marktinformatie

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 okt 2025, 19:33 UTC

Winsten

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

96.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.4 USD 96.21%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.